시장보고서

상품코드

1482328

오피오이드 시장 규모 및 예측 : 세계 및 지역 점유율, 동향, 성장 기회 분석 리포트 - 제품별, 용도별, 투여 경로별, 유통 채널별, 지역별

Opioids Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Application, Route Of Administration, Distribution Channel, and Geography

발행일: 2024년 05월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 209 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

오피오이드 시장은 2023년 129억 3,000만 달러에서 2031년에는 150억 3,000만 달러로 성장할 것으로 예상되며, 2023-2031년의 CAGR은 1.9%를 기록할 것으로 예측됩니다.

오피오이드는 주로 통증 완화를 위해 사용되는 광범위한 의약품군입니다. 이 약물은 매우 효과적이지만 중독을 유발할 수 있습니다. 오피오이드는 뇌의 수용체에 작용하여 진통 등 다양한 효과를 나타냅니다. 오피오이드에는 헤로인, 모르핀, 코데인, 펜타닐, 메타돈, 트라마돌 및 기타 유사 물질이 포함됩니다. 오피오이드 시장 규모가 확대되는 배경에는 전 세계에서 만성 통증이 급증하고 있다는 점이 있습니다. 또한 전 세계에서 노인 인구가 증가하고 있는 것도 오피오이드 시장의 성장에 박차를 가하고 있습니다. 오피오이드 과다복용과 장애를 예방하고 치료할 수 있는 약물을 개발하는 데 중점을 둔 정부의 구상은 예측 기간 중 새로운 오피오이드 시장 동향을 가져올 가능성이 높습니다.

시장 기업의 전략적 노력이 오피오이드 시장 성장의 기회를 창출합니다.

오피오이드 시장 기업은 효과적인 제품 개발을 위해 R&D 활동에 투자하고 있으며, 2023년 5월 Indivior PLC는 12세 이상의 성인 및 소아 환자에서 합성 또는 천연 오피오이드에 의해 유발된 오피오이드 과다복용이 의심되거나 알려진 오피오이드 과다복용을 치료하기 위한 긴급 치료제로서 중추신경계 및/또는 호흡 억제를 특징으로 하는 OPVEE(나르메펜) 비강 스프레이에 대한 미국 식품의약국(FDA)의 승인을 획득했습니다. 또한 Sandoz는 2021년 12월 미국에서 나르칸(Narcan, 나록손 염산염) 비강 분무제 4mg 제네릭을 출시할 예정이라고 밝혔습니다. 이 제품은 오피오이드 과다복용을 억제하는 제품으로, 미국내 소매 약국이나 병원 등 의료기관에서 즉시 구입할 수 있습니다. 마지막으로 2023년 8월, Emergent BioSolutions는 NARCAN 비강 스프레이를 시판하여 누구나 오피오이드 과다복용 응급상황에서 생명을 구할 수 있게 되었습니다. 따라서 전략적 구상은 향후 수년간 오피오이드 시장에 성장 기회를 제공할 가능성이 높습니다.

지역별로 오피오이드 시장은 북미(미국, 캐나다, 멕시코), 유럽(영국, 독일, 프랑스, 이탈리아, 스페인, 러시아, 기타 유럽), 아시아태평양(중국, 일본, 인도, 한국, 호주, 동남아시아, 기타 아시아태평양), 중동 및 아프리카(아랍에미리트, 사우디아라비아, 남아프리카공화국, 호주, 동남아시아, 기타 중동 및 아프리카), 남미 및 중남미(브라질, 아르헨티나, 기타 중동 및 아프리카)로 나뉩니다. 아랍에미리트, 사우디아라비아, 남아프리카공화국, 호주, 동남아시아, 기타 중동/아프리카), 남미/중미(브라질, 아르헨티나, 기타 중동/아프리카)로 구분됩니다. 북미는 2023년 세계 오피오이드 시장에서 가장 큰 점유율을 차지했습니다. 그러나 아시아태평양은 2023-2031년 가장 높은 CAGR을 나타낼 것으로 예상됩니다. 미국은 2022년 북미 오피오이드 시장에서 가장 큰 점유율을 차지했습니다. 미국 시장 기업은 오피오이드 시장 개척을 위해 유기적, 무기적 전략을 채택하고 있습니다. 예를 들어 2024년 Hikma Pharmaceuticals PLC는 25mcg/0.5mL 및 50mcg/mL 용량의 Fentanyl Citrate Injection, USP를 출시했으며, FDA가 승인한 최초의 25mcg/0.5mL 제제를 미국 시장에 출시하였습니다. 미국 시장에 출시했습니다. 이번 출시로 회사는 포트폴리오를 확장하고 병원이 이용할 수 있는 의약품의 선택권을 넓힐 것으로 기대하고 있습니다. 또한 2023년 루산제약은 인도 마디아 프라데시 주에 최첨단 원료의약품 생산시설을 설립했습니다. 이 시설은 엄격한 국제 규제 가이드라인을 준수하도록 설계되어 최고 수준의 규정 준수를 보장합니다. 연간 400톤의 원료의약품 생산 능력을 갖추고 있습니다. 이번 시설 확장은 인도 및 세계 중독 치료 및 통증 관리 제품에 대한 수요 증가에 대응하기 위해 중요한 원료의약품을 안정적으로 공급할 수 있게 되었습니다. 또한 2023년 뉴락스팜은 사노피로부터 중추신경계 질환, 통증 및 혈관 질환 분야에서 두 개의 확립된 제품 포트폴리오를 인수했다고 발표했습니다. 뉴락스팜이 인수한 기존 제품에는 중추신경계 질환 관련 15개 제품, 통증 및 혈관 질환 관련 2개 제품이 포함되며, 2022년에는 콜레기움 파마슈티컬이 바이오딜리버리 사이언스 인터내셔널(BDSI)의 인수를 완료했다고 발표했습니다. BDSI의 상업적 성장의 원동력인 BELBUCA는 스케줄 III 오피오이드 제품인 BELBUCA로, 콜레기움의 통증 제품 포트폴리오와 높은 상호 보완성을 가지고 있습니다. 이러한 요인들이 시장 성장을 지원하고 있습니다.

오피오이드 시장 - 주요 시장 역학
시장 촉진요인
- 만성 통증의 급증
- 노년 인구의 증가
시장 억제요인
- 약물 남용의 증가
시장 기회
- 시장 기업의 전략적 구상
향후 동향
- 오피오이드 과잉 섭취와 장애를 예방·치료하는 약의 개발에 초점을 맞춘 정부의 구상
촉진요인과 억제요인의 영향

제6장 오피오이드 시장 : 세계 시장 분석

오피오이드 시장의 매출, 2022-2030년
오피오이드 시장 예측 분석

제7장 오피오이드 시장 분석 : 제품별

즉시 방출 단시간 작용형 오피오이드
서방성 장시간 작용형 오피오이드

제8장 오피오이드 시장 분석 : 용도별

통증 관리
마취제
설사 억제
기침 억제
탈중독
기타

제9장 오피오이드 시장 분석 : 투여 경로별

경구
주사제
경피 패치

제10장 오피오이드 시장 분석 : 유통 채널별

병원 약국
소매 약국

제11장 오피오이드 시장 분석 : 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- APAC 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제12장 업계 상황

오피오이드 시장의 성장 전략
유기적 성장 전략
무기적 성장 전략
- 성장 전략

제13장 기업 개요

Purdue Pharma LP
Endo International plc
Mallinckrodt Plc
Collegium Pharmaceutical Inc
Neuraxpharm Pharmaceuticals SL
Hikma Pharmaceuticals Plc
Mayne Pharma Group Ltd
Rusan Pharma Ltd
Trevena Inc
Teva Pharmaceutical Industries Ltd

제14장 부록

KSA 24.05.31

The Opioids market is expected to grow from US$ 12.93 billion in 2023 to US$ 15.03 billion by 2031; it is anticipated to record a CAGR of 1.9% from 2023 to 2031.

Opioids are a broad group of medicines majorly used for relieving pain. These medicines are highly effective but can also leads to an addiction. Opioid acts by working on brain receptors and thus provide the varieties of effect including the pain relief. Opioid includes heroin, morphine, codeine, fentanyl, methadone, tramadol, and other similar substances. The growing opioids market size is attributed to the surging chronic pain incidences across the world. In addition, the increasing geriatric population across the world are fueling opioid market growth. A government initiative focusing on the development of medication to prevent and treat opioid overdose and disorders is likely to bring new opioids market trends during the forecast period.

Strategic Initiatives by Market Players will Create an Opportunity for Opioid market growth.

Opioids market players invest in R&D activities to ensure the development of effective products. In May 2023, Indivior PLC received the US Food and Drug Administration (FDA) approval for OPVEE (nalmefene) nasal spray for emergency use to treat suspected or known opioid overdose induced by synthetic or natural opioids in adults and pediatric patients aged 12 years and more, which is characterized by CNS and/or respiratory depression. Further, in December 2021, Sandoz announced the launch of its generic Narcan (naloxone hydrochloride) Nasal Spray 4mg in the US; the product is used to reverse opioid overdose. Individuals in the US can immediately obtain Narcan via retail pharmacies and institutions, including hospitals. Lastly, in August 2023, Emergent BioSolutions launched the over-the-counter NARCAN Nasal Spray, making it possible for everybody to help save a life from an opioid overdose emergency. Therefore, strategic initiatives are likely to offer growth opportunities to the opioids market in the coming years.

Based on geography, the Opioid market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global Opioid market in 2023 owing to the lifestyle factor. However, Asia Pacific is predicted to register the highest CAGR during 2023-2031. The US held the largest share of the Opioid market in North America in 2022. US market players are adopting organic and inorganic strategies for Opioid market development. For instance, in 2024, Hikma Pharmaceuticals PLC launched Fentanyl Citrate Injection, USP, in 25mcg/0.5mL and 50mcg/mL doses. Hikma introduced the first FDA approved 25mcg/0.5mL presentation to the US market. The company is expected to expand its portfolio with the launch, broadening the choice of medicines available to hospitals. Furthermore, in 2023, Rusan Pharma launched its state-of-the-art API facility in Madhya Pradesh, India. The facility is designed to meet stringent international regulatory guidelines, ensuring the highest level of compliance. With the production capability of 400 metric tons of APIs annually. This facility expansion will ensure the security of supply of critical APIs to meet the growing demand for addiction treatment and pain management products in India and globally. Moreover in 2023, Neuraxpharm announced the closing of the acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. The well-established products that Neuraxpharm acquired includes 15 products addressing CNS disorders and two products in pain and vascular diseases, and in 2022, Collegium Pharmaceutical, Inc. announced that it completed the acquisition of BioDelivery Sciences International Inc. BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions. BDSI's commercial growth driver, BELBUCA, is a meaningfully differentiated schedule III opioid product and is highly complementary to Collegium's portfolio of pain products. Thus, the factors mentioned above support the market growth.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Opioids Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Opioids Market - Key Market Dynamics

5.1 Opioids Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Surging Chronic Pain Incidence
- 5.2.2 Increasing Geriatric Population
5.3 Market Restraints
- 5.3.1 Increasing Drug Abuse
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
- 5.5.1 Government Initiatives Focusing on Development of Medication to Prevent and Treat Opioid Overdose and Disorder
5.6 Impact of Drivers and Restraints:

6. Opioids Market - Global Market Analysis

6.1 Opioids Market Revenue (US$ Million), 2022-2030
6.2 Opioids Market Forecast Analysis

7. Opioids Market Analysis - by Product

7.1 Immediate Release Short Acting Opioid
- 7.1.1 Overview
- 7.1.2 Immediate Release Short Acting Opioid: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.1.2.1 Global Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
7.2 Extended Release Long-Acting Opioid
- 7.2.1 Overview
- 7.2.2 Extended Release Long-Acting Opioid: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.2.2.1 Global Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

8. Opioids Market Analysis - by Application

8.1 Pain Management
- 8.1.1 Overview
- 8.1.2 Pain Management: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Anesthesia
- 8.2.1 Overview
- 8.2.2 Anesthesia: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Diarrhoea Suppression
- 8.3.1 Overview
- 8.3.2 Diarrhoea Suppression: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Cough Suppression
- 8.4.1 Overview
- 8.4.2 Cough Suppression: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.5 De-Addiction
- 8.5.1 Overview
- 8.5.2 De-Addiction: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Opioids Market Analysis - by Route of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Injectable
- 9.2.1 Overview
- 9.2.2 Injectable: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Transdermal Patch
- 9.3.1 Overview
- 9.3.2 Transdermal Patch: Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Opioids Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: Opioids Market - Revenue and Forecast to 2030 (US$ Million)

11. Opioids Market - Geographical Analysis

11.1 Overview
11.2 North America
- 11.2.1 North America Opioids Market Overview
- 11.2.2 North America: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 11.2.2.1 North America: Opioids Market - Revenue and Forecast Analysis - by Product
- 11.2.3 North America: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
  - 11.2.3.1 North America: Opioids Market - Revenue and Forecast Analysis - by Immediate Release Short Acting Opioid
  - 11.2.3.2 North America: Opioids Market - Revenue and Forecast Analysis - by Extended Release Long-Acting Opioid
  - 11.2.3.3 North America: Opioids Market - Revenue and Forecast Analysis - by Application
- 11.2.4 North America: Opioids Market Breakdown, by Route of Administration
  - 11.2.4.1 North America: Opioids Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.2.4.2 North America: Opioids Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.5 North America: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.2.5.1 North America: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.2.5.2 United States: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.5.2.1 United States: Opioids Market Breakdown, by Product
    - 11.2.5.2.2 United States: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.2.5.2.3 United States: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.2.5.2.4 United States: Opioids Market Breakdown, by Application
    - 11.2.5.2.5 United States: Opioids Market Breakdown, by Route of Administration
    - 11.2.5.2.6 United States: Opioids Market Breakdown, by Distribution Channel
  - 11.2.5.3 Canada: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.5.3.1 Canada: Opioids Market Breakdown, by Product
    - 11.2.5.3.2 Canada: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.2.5.3.3 Canada: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.2.5.3.4 Canada: Opioids Market Breakdown, by Application
    - 11.2.5.3.5 Canada: Opioids Market Breakdown, by Route of Administration
    - 11.2.5.3.6 Canada: Opioids Market Breakdown, by Distribution Channel
  - 11.2.5.4 Mexico: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.2.5.4.1 Mexico: Opioids Market Breakdown, by Product
    - 11.2.5.4.2 Mexico: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.2.5.4.3 Mexico: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.2.5.4.4 Mexico: Opioids Market Breakdown, by Application
    - 11.2.5.4.5 Mexico: Opioids Market Breakdown, by Route of Administration
    - 11.2.5.4.6 Mexico: Opioids Market Breakdown, by Distribution Channel
11.3 Europe
- 11.3.1 Europe Opioids Market Overview
- 11.3.2 Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
- 11.3.3 Europe: Opioids Market Breakdown, by Product
  - 11.3.3.1 Europe: Opioids Market - Revenue and Forecast Analysis - by Product
  - 11.3.3.2 Europe: Opioids Market - Revenue and Forecast Analysis - by Immediate Release Short Acting Opioid
  - 11.3.3.3 Europe: Opioids Market - Revenue and Forecast Analysis - by Extended Release Long-Acting Opioid
  - 11.3.3.4 Europe: Opioids Market - Revenue and Forecast Analysis - by Application
  - 11.3.3.5 Europe: Opioids Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.3.3.6 Europe: Opioids Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.4 Europe: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.3.4.1 Europe: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.3.4.2 United Kingdom: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.4.2.1 United Kingdom: Opioids Market Breakdown, by Product
    - 11.3.4.2.2 United Kingdom: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.3.4.2.3 United Kingdom: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.3.4.2.4 United Kingdom: Opioids Market Breakdown, by Application
    - 11.3.4.2.5 United Kingdom: Opioids Market Breakdown, by Route of Administration
    - 11.3.4.2.6 United Kingdom: Opioids Market Breakdown, by Distribution Channel
  - 11.3.4.3 Germany: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.4.3.1 Germany: Opioids Market Breakdown, by Product
    - 11.3.4.3.2 Germany: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.3.4.3.3 Germany: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.3.4.3.4 Germany: Opioids Market Breakdown, by Application
    - 11.3.4.3.5 Germany: Opioids Market Breakdown, by Route of Administration
    - 11.3.4.3.6 Germany: Opioids Market Breakdown, by Distribution Channel
  - 11.3.4.4 France: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.4.4.1 France: Opioids Market Breakdown, by Product
    - 11.3.4.4.2 France: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.3.4.4.3 France: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.3.4.4.4 France: Opioids Market Breakdown, by Application
    - 11.3.4.4.5 France: Opioids Market Breakdown, by Route of Administration
    - 11.3.4.4.6 France: Opioids Market Breakdown, by Distribution Channel
  - 11.3.4.5 Italy: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.4.5.1 Italy: Opioids Market Breakdown, by Product
    - 11.3.4.5.2 Italy: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.3.4.5.3 Italy: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.3.4.5.4 Italy: Opioids Market Breakdown, by Application
    - 11.3.4.5.5 Italy: Opioids Market Breakdown, by Route of Administration
    - 11.3.4.5.6 Italy: Opioids Market Breakdown, by Distribution Channel
  - 11.3.4.6 Spain: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.4.6.1 Spain: Opioids Market Breakdown, by Product
    - 11.3.4.6.2 Spain: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.3.4.6.3 Spain: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.3.4.6.4 Spain: Opioids Market Breakdown, by Application
    - 11.3.4.6.5 Spain: Opioids Market Breakdown, by Route of Administration
    - 11.3.4.6.6 Spain: Opioids Market Breakdown, by Distribution Channel
  - 11.3.4.7 Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.3.4.7.1 Rest of Europe: Opioids Market Breakdown, by Product
    - 11.3.4.7.2 Rest of Europe: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.3.4.7.3 Rest of Europe: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.3.4.7.4 Rest of Europe: Opioids Market Breakdown, by Application
    - 11.3.4.7.5 Rest of Europe: Opioids Market Breakdown, by Route of Administration
    - 11.3.4.7.6 Rest of Europe: Opioids Market Breakdown, by Distribution Channel
11.4 Asia Pacific
- 11.4.1 Asia Pacific Opioids Market Overview
- 11.4.2 Asia Pacific: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 11.4.2.1 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Product
  - 11.4.2.2 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Immediate Release Short Acting Opioid
  - 11.4.2.3 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Extended Release Long-Acting Opioid
  - 11.4.2.4 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Application
  - 11.4.2.5 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.4.2.6 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.3 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.1 Asia Pacific: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.2 China: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.3.2.1 China: Opioids Market Breakdown, by Product
    - 11.4.3.2.2 China: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.4.3.2.3 China: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.4.3.2.4 China: Opioids Market Breakdown, by Application
    - 11.4.3.2.5 China: Opioids Market Breakdown, by Route of Administration
    - 11.4.3.2.6 China: Opioids Market Breakdown, by Distribution Channel
  - 11.4.3.3 Japan: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.3.3.1 Japan: Opioids Market Breakdown, by Product
    - 11.4.3.3.2 Japan: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.4.3.3.3 Japan: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.4.3.3.4 Japan: Opioids Market Breakdown, by Application
    - 11.4.3.3.5 Japan: Opioids Market Breakdown, by Route of Administration
    - 11.4.3.3.6 Japan: Opioids Market Breakdown, by Distribution Channel
  - 11.4.3.4 India: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.3.4.1 India: Opioids Market Breakdown, by Product
    - 11.4.3.4.2 India: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.4.3.4.3 India: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.4.3.4.4 India: Opioids Market Breakdown, by Application
    - 11.4.3.4.5 India: Opioids Market Breakdown, by Route of Administration
    - 11.4.3.4.6 India: Opioids Market Breakdown, by Distribution Channel
  - 11.4.3.5 South Korea: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.3.5.1 South Korea: Opioids Market Breakdown, by Product
    - 11.4.3.5.2 South Korea: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.4.3.5.3 South Korea: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.4.3.5.4 South Korea: Opioids Market Breakdown, by Application
    - 11.4.3.5.5 South Korea: Opioids Market Breakdown, by Route of Administration
    - 11.4.3.5.6 South Korea: Opioids Market Breakdown, by Distribution Channel
  - 11.4.3.6 Australia: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.3.6.1 Australia: Opioids Market Breakdown, by Product
    - 11.4.3.6.2 Australia: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.4.3.6.3 Australia: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.4.3.6.4 Australia: Opioids Market Breakdown, by Application
    - 11.4.3.6.5 Australia: Opioids Market Breakdown, by Route of Administration
    - 11.4.3.6.6 Australia: Opioids Market Breakdown, by Distribution Channel
  - 11.4.3.7 Rest of APAC: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.4.3.7.1 Rest of APAC: Opioids Market Breakdown, by Product
    - 11.4.3.7.2 Rest of APAC: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.4.3.7.3 Rest of APAC: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.4.3.7.4 Rest of APAC: Opioids Market Breakdown, by Application
    - 11.4.3.7.5 Rest of APAC: Opioids Market Breakdown, by Route of Administration
    - 11.4.3.7.6 Rest of APAC: Opioids Market Breakdown, by Distribution Channel
11.5 Middle East and Africa
- 11.5.1 Middle East and Africa Opioids Market Overview
- 11.5.2 Middle East and Africa: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 11.5.2.1 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Product
  - 11.5.2.2 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Immediate Release Short Acting Opioid
  - 11.5.2.3 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Extended Release Long-Acting Opioid
  - 11.5.2.4 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Application
  - 11.5.2.5 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.5.2.6 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Distribution Channel
  - 11.5.2.7 Middle East and Africa: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.5.2.8 Saudi Arabia: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.2.8.1 Saudi Arabia: Opioids Market Breakdown, by Product
    - 11.5.2.8.2 Saudi Arabia: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.5.2.8.3 Saudi Arabia: Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 11.5.2.8.4 Saudi Arabia: Opioids Market Breakdown, by Application
    - 11.5.2.8.5 Saudi Arabia: Opioids Market Breakdown, by Route Of Administration
    - 11.5.2.8.6 Saudi Arabia: Opioids Market Breakdown, by Distribution Channel
  - 11.5.2.9 South Africa: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.2.9.1 South Africa: Opioids Market Breakdown, by Product
    - 11.5.2.9.2 South Africa: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.5.2.9.3 South Africa: Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 11.5.2.9.4 South Africa: Opioids Market Breakdown, by Application
    - 11.5.2.9.5 South Africa: Opioids Market Breakdown, by Route Of Administration
    - 11.5.2.9.6 South Africa: Opioids Market Breakdown, by Distribution Channel
  - 11.5.2.10 United Arab Emirates: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.2.10.1 United Arab Emirates: Opioids Market Breakdown, by Product
    - 11.5.2.10.2 United Arab Emirates: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.5.2.10.3 United Arab Emirates: Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 11.5.2.10.4 United Arab Emirates: Opioids Market Breakdown, by Application
    - 11.5.2.10.5 United Arab Emirates: Opioids Market Breakdown, by Route Of Administration
    - 11.5.2.10.6 United Arab Emirates: Opioids Market Breakdown, by Distribution Channel
  - 11.5.2.11 Rest of Middle East and Africa: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.5.2.11.1 Rest of Middle East and Africa: Opioids Market Breakdown, by Product
    - 11.5.2.11.2 Rest of Middle East and Africa: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.5.2.11.3 Rest of Middle East and Africa: Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 11.5.2.11.4 Rest of Middle East and Africa: Opioids Market Breakdown, by Application
    - 11.5.2.11.5 Rest of Middle East and Africa: Opioids Market Breakdown, by Route Of Administration
    - 11.5.2.11.6 Rest of Middle East and Africa: Opioids Market Breakdown, by Distribution Channel
11.6 South and Central America
- 11.6.1 South and Central America Opioids Market Overview
- 11.6.2 South and Central America: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 11.6.2.1 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Product
  - 11.6.2.2 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Immediate Release Short Acting Opioid
  - 11.6.2.3 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Extended Release Long Acting Opioid
  - 11.6.2.4 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Application
  - 11.6.2.5 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.6.2.6 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.6.3 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.6.3.1 South and Central America: Opioids Market - Revenue and Forecast Analysis - by Country
  - 11.6.3.2 Brazil: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.6.3.2.1 Brazil: Opioids Market Breakdown, by Product
    - 11.6.3.2.2 Brazil: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.6.3.2.3 Brazil: Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 11.6.3.2.4 Brazil: Opioids Market Breakdown, by Application
    - 11.6.3.2.5 Brazil: Opioids Market Breakdown, by Route Of Administration
    - 11.6.3.2.6 Brazil: Opioids Market Breakdown, by Distribution Channel
  - 11.6.3.3 Argentina: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.6.3.3.1 Argentina: Opioids Market Breakdown, by Product
    - 11.6.3.3.2 Argentina: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.6.3.3.3 Argentina: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
    - 11.6.3.3.4 Argentina: Opioids Market Breakdown, by Application
    - 11.6.3.3.5 Argentina: Opioids Market Breakdown, by Route Of Administration
    - 11.6.3.3.6 Argentina: Opioids Market Breakdown, by Distribution Channel
  - 11.6.3.4 Rest of South and Central America: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.6.3.4.1 Rest of South and Central America: Opioids Market Breakdown, by Product
    - 11.6.3.4.2 Rest of South and Central America: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 11.6.3.4.3 Rest of South and Central America: Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 11.6.3.4.4 Rest of South and Central America: Opioids Market Breakdown, by Application
    - 11.6.3.4.5 Rest of South and Central America: Opioids Market Breakdown, by Route Of Administration
    - 11.6.3.4.6 Rest of South and Central America: Opioids Market Breakdown, by Distribution Channel

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in Opioids Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Purdue Pharma LP
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Endo International plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Mallinckrodt Plc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Collegium Pharmaceutical Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Neuraxpharm Pharmaceuticals SL
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Hikma Pharmaceuticals Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Mayne Pharma Group Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Rusan Pharma Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Trevena Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Teva Pharmaceutical Industries Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms